Bristol Myers Iberdomide NDA Gains FDA Priority Review with August 17 Deadline
The FDA has accepted Bristol Myers Squibb’s NDA for iberdomide in relapsed or refractory multiple myeloma and granted Priority Review and Breakthrough Therapy Designation, targeting an August 17 decision. The application is supported by Phase 3 EXCALIBER-RRMM data using MRD negativity as the primary endpoint with daratumumab and dexamethasone.
1. FDA Acceptance and Review Timeline
On February 17, the FDA accepted the New Drug Application for iberdomide in relapsed or refractory multiple myeloma and granted both Priority Review and Breakthrough Therapy Designation, setting a target action date of August 17. These designations accelerate review timelines and signal strong potential based on preliminary data.
2. Phase 3 EXCALIBER-RRMM Trial Highlights
The submission is backed by Phase 3 EXCALIBER-RRMM results, where iberdomide combined with daratumumab and dexamethasone was compared against a standard three-drug regimen. The trial’s primary endpoint was Minimal Residual Disease (MRD) negativity, a sensitive measure of residual cancer cells linked to longer remission.
3. Iberdomide Mechanism and Pipeline Implications
Iberdomide is the first in a novel class of oral cereblon E3 ligase modulators, designed to tag cancer-promoting proteins for degradation. Its approval would expand Bristol Myers Squibb’s immunomodulatory portfolio with a potentially more potent and manageable oral therapy for multiple myeloma patients.